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With the rise of drug resistant strains of Mycobacterium tuberculosis (Mtb) and lags in 
antimicrobial drug development, it is imperative to explore alternative methods of treatment 
through host-directed adjunct therapies. Hallmarks of Mtb infection are altered host cell glucose 
metabolism and non-diabetic hyperglycemia, which increase disease severity and bacterial 
burden. This can be targeted using a combination of metformin and 2-deoxyglucose (2DG) to 
lower systemic blood glucose and increase metabolic stress in infected macrophages to induce 
apoptotic cell death, enabling Mtb clearance and antigen presentation to activate cell-mediated 
immune responses. We hypothesized that bacterial survival is aided by glycolysis-dependent 
macrophages, which can be targeted using a combination of metformin and 2DG to strengthen 
host immune responses. Using an in vitro model of guinea pig bone marrow derived 
macrophages under normal and high glucose conditions, we determined that both basal 
respiration and glycolytic activity increased after infection. When singly treated, metformin 
inhibited basal respiration while increasing glycolysis while 2DG inhibited both processes. In 
combination metformin and 2DG treatment inhibited basal respiration more effectively than 
metformin treatment alone and inhibited glycolysis as effectively as 2DG by itself. Efficacy of 
metformin-2DG treatment is dependent on high cellular glycolytic activity, a characteristic of 
granulomatous cells. Metformin-2DG treatment decreased cell survival 48 hours post-treatment 
by increasing apoptotic cell death and decreased Mtb survival more effectively than metformin 
or 2DG alone. We conclude that apoptotic induction of macrophages by metformin-2DG 
treatment may be a viable adjunct treatment to antimicrobial drugs to reduce bacterial burden 
and increase an effective host adaptive immune response.  
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Tuberculosis is a widespread, potentially fatal infectious disease affecting the lungs and 
other organs of the body. In the year 2014 alone, there were 9.6 million new tuberculosis (TB) 
cases and 1.5 million TB-related deaths, outranking HIV as the number one cause of death due 
to an infectious disease worldwide1. While only 12% of immune-competent individuals may 
develop active disease, the remaining 88% of individuals who develop an asymptomatic, latent 
infection are still at risk of developing active disease if left untreated2.  
Mycobacterium tuberculosis (Mtb), the causative agent of TB, has developed to coexist 
among and within us, with the oldest confirmed case having occurred over 9,000 years ago3. 
Today, Mtb continues to evolve to maintain this coexistence even in the presence of 
antimicrobial therapies, leading to the development of drug-resistant TB cases. In 2014, there 
were 480,000 new cases of multidrug-resistant (MDR) TB, comprising 3.3% of total new cases. 
While antimicrobial regimens for drug-susceptible TB require a minimum of 6 months treatment, 
MDR TB regimens last at least 21 months with an average success rate of only 50%1. 
Complicating matters further are the serious adverse side effects to antimicrobial therapy, which 
include liver and kidney toxicity as well as hearing and vision impairment4. Therefore, there is a 
need to explore alternate treatments such as the application of host-directed adjunct therapies 
to current antimicrobials to enhance drug efficacy as well as decrease the intensity and duration 
of treatment regimens. 
II. Macrophage Infection by Mycobacterium tuberculosis  
TB is an airborne disease transmitted by inhalation of aerosolized droplets containing 
Mtb from expectorating individuals with active disease5. Upon inhalation, Mtb is phagocytosed 
by resident alveolar macrophages where Mtb can undergo unrestricted replication5-8. Infected 
phagocytes migrate into lung interstitium and can disseminate to other organs via the lymphatic 
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system5,7. However phagocytes typically remain in the lungs and, in immune-competent 
individuals, form a granulomatous lesion composed primarily of mature macrophages followed 
by a combination of other leukocytes, lymphocytes, and epithelial cells5,8. While the granuloma 
serves as a method of Mtb sequestration and host protection, it is also considered a failed host 
immune response to bacterial clearance enabling Mtb survival8. 
Once encapsulated in a macrophage phagosome, Mtb secretes a number of lipid and 
protein effectors to prevent phagosomal maturation, the main microbicidal mechanism of 
macrophages9. Phagosomal maturation is the process where phagosomes interact with 
endosomes and lysosomes leading to the acidification of the Mtb-containing phagosome and 
exposure to proteolytic enzymes and reactive oxygen intermediates to clear the bacilli10,11. 
However, only 30% of Mtb-containing phagosomes are able to mature and destroy Mtb, 


















Figure 1.1 Intracellular fates of M. tuberculosis 
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III. Macrophage Polarization 
A. Activation and Functionality 
Macrophages alter their functionality through a process known as polarization. 
Depending on the signals they receive, macrophages are either classically activated and adopt 
a pro-inflammatory phenotype or alternatively activated, adopting an anti-inflammatory 
phenotype12-14. Classically activated, or M1, macrophages respond to type 1 inflammatory 
cytokines such as tumor necrosis factor alpha (TNFα) and microbial products enabling the 
production of nitric oxide (NO) and other reactive oxygen species (ROS) for antimicrobial 
activity7,15. Alternatively activated, or M2, macrophages respond to type 2 cytokines, such as 
interleukin 10 (IL-10), to resolve inflammation and promote tissue repair and angiogenesis14,15. 
While polarization results in two distinct cellular functional phenotypes, macrophages are highly 
plastic. Therefore, the same macrophage that drives a pro-inflammatory response may later aid 
in its resolution13. 
B. Mtb Infection 
During acute Mtb infection, macrophages are classically activated by stimulation of toll-
like receptors 2, 4, and 912,13,16. However, Mtb can subvert this response both directly and 
indirectly via virulence factors, such as early secreted antigenic target protein-6 (ESAT-6)12. 
Additionally, Mtb can promote an M2 phenotype by increasing IL-10 production, rendering the 
cells poorly bactericidal with reduced antigen presentation capabilities15. Granulomas contain 
both macrophage polarities, however centrally located Mtb-infected macrophages are 
predominantly classically activated, while those uninfected along the periphery express the M2 
phenotype17,18. This combination plays a dual role by (1) preserving lung tissue while 
sequestering the infection and (2) attempting to clear Mtb7.   
IV. Macrophage Metabolism 
Macrophages are dependent on glucose as compared to fatty acids or amino acids to 
derive their energy19. However the way in which these cells metabolize glucose is dependent on 
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their state of polarity and activation. Therefore quiescent and M2 macrophages have a different 
metabolic profile than M1, activated macrophages (Figure 1.2).  
A. Glucose Utilization Pathways 
To generate adenosine triphosphate (ATP) from a single molecule of glucose, 
homeostatic cells utilize three pathways: (1) glycolysis, (2) the tricarboxylic acid (TCA) cycle, 
and (3) oxidative phosphorylation. Using a glucose transporter, glucose enters the cell 
cytoplasm and begins the oxidation process of glycolysis, where it is converted into two 
pyruvate molecules. This occurs via a 9-step process starting with the phosphorylation of 
glucose by the enzyme hexokinase. The net gain of this process is 2 ATP, 2 pyruvate molecules, 
and 2 reduced molecules of the coenzyme nicotinamide adenine dinucleotide (NADH). Pyruvate 
can convert to lactate by lactate dehydrogenase (LDH) within the cytoplasm or enter into the 
inner mitochondrial matrix and convert to acetyl coenzyme A (acetyl-CoA) by the pyruvate 
dehydrogenase complex. Within the mitochondria, acetyl-CoA can enter the TCA cycle, where it 
is further oxidized into 8 different substrate intermediates including citrate, α-ketoglutarate, 
succinate, and oxaloacetate. Under these conditions, the TCA cycle breaks down its 






Figure 1.2 Macrophage metabolic pathways under different polarities. Image modified from Pearce, E. J. & Everts, B. Dendritic cell metabolism. 
Nature reviews. Immunology 15, 18-29, doi:10.1038/nri3771 (2015)   
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formed: 3 NADH coenzymes, 1 reduced flavin adenine dinucleotide (FADH2) coenzyme, 2 CO2 
molecules, and 1 ATP per molecule of acetyl-CoA. Generated NADH is oxidized via complex I 
of the electron transport chain (ETC), also known as NADH dehydrogenase. Complex II, or 
succinate dehydrogenase, which is responsible for the reduction of FADH2 in the TCA cycle, 
also contributes electrons to the ETC. The coenzyme oxidation releases electrons into the chain 
where they flow through coenzyme Q, complex III, cytochrome c, and complex IV, the final 
electron acceptor. This flow of electrons functions to form a proton gradient between the inner 
and inter-membrane mitochondrial spaces by driving hydrogen ions out of the inner 
mitochondrial matrix through ETC complexes I through IV. The polarization of this gradient 
drives ATP synthase to phosphorylate one molecule of adenosine diphosphate (ADP) into ATP. 
Overall, one molecule of glucose will generate approximately 36 ATP: 2 ATP from glycolysis, 2 
ATP from the TCA cycle, and approximately 32 ATP from the ETC (Figure 1.2)19. 
Whereas quiescent and M2 macrophages primarily utilize oxidative phosphorylation, M1 
activated macrophages will preferentially utilize glycolysis to generate ATP. While this metabolic 
shift was long known to occur under oxygen-poor conditions, it was noted in the 1920s by Otto 
Warburg that ATP generation from glycolysis could also occur in the presence of oxygen, 
terming this process “aerobic glycolysis”16. While glycolysis only produces 2 ATP, it is 
catabolically more efficient at generating energy as there are fewer processes required20. As 
pyruvate converts to lactate by lactate dehydrogenase, the NADH produced in glycolysis is 
reoxidized to NAD+, which can be reused in additional glycolytic processes to generate more 
ATP19. This shift allows the mitochondria to generate ROS through its ETC, and change the 
TCA cycle to an anabolic state where it can generate intermediates for fatty acid and amino acid 
biosynthesis that contribute to pro-inflammatory processes, such as the generation of 
prostaglandins via the arachidonic acid pathway21,22. Upon activation by Mtb, M1 macrophages 
will perform aerobic glycolysis to aid in their bactericidal function. Alternately, M2 macrophages 
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rely on oxidative phosphorylation to sustain their energy to serve their long-term regenerative 
function (Figure 1.2)21. 
B. Glucose Utilization in the Granuloma 
Initially developed as a cancer diagnostic, positron emission tomography-computed 
tomography (PET-CT) has recently been investigated as a diagnostic for discerning active 
versus latent TB in patients (Figure 1.3 A)23. PET-CT defines areas of increased glucose 
demand using fluoro-18-deoxyglucose (18FDG), a radioactive glucose analog24. While there are 
sites of normal physiologic glucose accumulation, such as the heart and brain, PET-CT also 
reveals pathologic sites of glucose accumulation where cells have increased metabolism due to 
inflammation or infection, such as the granuloma. Investigators determined that less 18FDG 
uptake in the lesion is associated with latent disease while more 18FDG accumulation is 
associated with active disease18. 
 
PET-CT has also been applied in atherosclerosis research to associate macrophage 
polarization within atherosclerotic plaques to 18FDG accumulation. Increased accumulation was 
associated with M1 macrophages versus M2 macrophages25. Additionally, a recent study 
focused on computational modeling of a granuloma and polarity demonstrated that M1 
Figure 1.3 Glucose accumulation and macrophage polarization within non-human primate granulomas. (A) PET-CT scan 
showing 18F-2DG accumulation and (B) immunohistochemistry of M1 (green) and M2 (purple) macrophages in granulomas. Images 
from  Coleman, M. T. et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with 
tuberculosis. Sci Transl Med 6, 265ra167, doi:10.1126/scitranslmed.3009500 (2014) and  Marino, S. et al. Macrophage polarization 
drives granuloma outcome during Mycobacterium tuberculosis infection. Infection and immunity 83, 324-338, doi:10.1128/IAI.
02494-14 (2015).  
A B 
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macrophages composed the majority of infected cells within the lesion, while M2 macrophages 
reside around the periphery to protect surrounding tissues (Figure 1.3 B)17. Increased lactate 
levels have also been observed within the lungs of Mtb infected guinea pigs using high 
resolution magic-angle spinning nuclear magnetic resonance (HRMAS-NMR). This study 
determined that cells within the granuloma are primarily dependent on aerobic glycolysis for 
ATP generation26. Therefore it is likely that granulomatous macrophages within a patient with 
active disease are predominantly in an M1 polarized state and are primarily glycolytic compared 
to those within latent TB patients, which likely have a predominant M2 macrophage profile.  
V. Chronic Hyperglycemia and Impaired Immune Function 
Stress hyperglycemia and impaired glucose tolerance are associated with inflammation 
and infection, including active Mtb infection27-30. Approximately 13 to 45 percent of patients with 
active TB demonstrate impaired glucose tolerance, but only 2 to 7 percent are diagnosed with 
diabetes mellitus31-33. We have demonstrated that under both acute and chronic disease states 
Mtb infected guinea pigs have increased glucose levels in their blood sera that results in 
increased disease severity34. Chronic hyperglycemia during Mtb infection results in increased 
bacillary loads in patient sputum samples, increased lesion cavitation, and poorer treatment 
outcomes to anti-TB therapy28.  
 On a cellular level, there remains conflicting evidence on the effects of high glucose 
conditions on macrophage function. While some studies demonstrate impaired pro-inflammatory 
responses to infection, others conclude an excessive inflammatory response to macrophage 
activation. Macrophages under hyperglycemic conditions have been described as having 
impaired microbicidal function including phagocytosis, cytokine secretion, and the production of 
ROS35-38. It is suggested that after long-term exposure to hyperglycemia M2 polarization may be 
the predominant macrophage phenotype36,37. However, there are other studies suggesting that 
increased extracellular glucose levels stimulate glycolysis, increasing M1 pro-inflammatory 
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responses38,39. Understanding these cellular responses may aid in our explanation of associated 
exacerbated disease severity to hyperglycemia. 
VI. Mechanisms of Cell Death and Mtb Survival and Dissemination 
There are three main classifications of cell death: necrosis, apoptosis, and autophagy. 
Necrosis is considered an inflammatory process due to its unregulated release of ROS and 
hydrolytic enzymes, and thus an undesirable cell death outcome40. Apoptosis and autophagy 
are regulated, self-contained processes that cause very little disturbance or inflammation to the 
surrounding environment, making them more favorable death mechanisms for granulomatous 
cells.  
Necrosis 
 Necrosis is cell death via swelling (oncosis) and disruption of plasma membrane integrity 
followed by release of cytoplasmic contents41. Virulent Mtb strains, such as H37Rv, promote 
cellular necrosis as a means of bacillary dissemination42. Cells can also undergo necrosis after 
rapid ATP depletion, which leads to mitochondrial permeability transition via decreased activity 
of the ATP-sodium-potassium pump43,44. Inhibition of metabolic stress survival pathways, such 
as autophagy, can also lead to necrosis44 .  
Apoptosis  
Apoptosis is cell death characterized by the morphologic features of cell shrinkage, 
membrane blebbing, and chromatin condensation (pyknosis)41. Mechanistically, apoptosis 
occurs via caspase protease activation either by the intrinsic mitochondrial pathway or the 
extrinsic death receptor pathway41. Two classes of caspases function within these pathways: (1) 
initiator caspases 2, 8 and 9, and (2) executioner caspases 3, 6 and 741. While initiator 
caspases are activated according to extrinsic or intrinsic apoptotic pathways, executioner 
caspases are activated via proteolytic cleavage causing a conformational change into a mature 
protease41. Functions of executioner caspases include cleavage of complex I of the ETC to 
disrupt mitochondrial membrane potential and ATP production, the activation of DNAse to 
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cleave chromatin, and activation of actin cytoskeleton modulators responsible for the 
characteristic membrane blebbing41.  
The intrinsic pathway, the most common apoptotic pathway, is triggered by cellular 
stress such as DNA damage and insufficient ATP levels41. These stimuli induce mitochondrial 
outer membrane permeabilization (MOMP) by Bcl2 pro-apoptotic proteins Bax and Bak41. 
MOMP causes cytochrome c release into the cytoplasm where it can bind to apoptotic protease 
activating factor 1 (APAF1) to form the apoptosome and activate caspase 9, leading to 
executioner caspase activation and apoptosis (Figure 1.4)41.  
The extrinsic pathway is signaled by the ligation of a death receptor, a subgroup of the 
tumor necrosis factor receptor family41. Once ligated, receptors such as Fas/CD95 or TNF-
related apoptosis-inducing ligand receptor (TRAIL-R1/R2) form a caspase-activation platform, 






















Figure 1.4 Intrinsic and extrinsic apoptotic pathways 
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directly activate executioner caspases 3 and 7 but more commonly will indirectly activate these 
caspases via cleavage of Bid, another pro-apoptotic protein, which subsequently activates Bax 
and Bak-mediated MOMP (Figure 1.4)41.  
Three benefits of undergoing apoptotic cell death are that (1) it eliminates Mtb’s 
replicating host niche, (2) it can activate adaptive immunity through antigen presentation, and 
(2) it forces Mtb to reestablish itself within a naïve host cell, decreasing its chances of survival42. 
Therefore, apoptotic cell death, particularly via an intrinsic pathway, is considered a favorable 
mechanism of cell death under Mtb infection40. 
Autophagy 
Autophagy, also known as “self-eating,” is a process in which materials from within the 
cytoplasm are delivered to a lysosome for degradation and recycling. While this is a normal 
physiologic process to clear damaged organelles, it is also a cell stress survival mechanism 
such as under nutrient scarcity or intracellular bacterial infection (xenophagy)41,46,47. If 
autophagy is unsuccessful at ameliorating the stressor, autophagic machinery can promote cell 
death through a variety of mechanisms that have yet to be determined41,46.  
Autophagy begins by the formation of a double membrane structure known as the 
autophagosome via a three-step process (Figure 1.5 A). First is the activation of the pre-
initiation complex Unc-51-like autophagy-activating kinase (ULK), which is negatively and 
positively regulated by the mammalian target of rapamycin complex I (mTORC1) and AMP-
activated protein kinase (AMPK), respectively41,42. If activated by AMPK, the pre-initiation 
complex will recruit and activate the initiation complex, which is negatively regulated by the Bcl2 
anti-apoptotic proteins Bcl2 and Bcl-xL41. Second is the elongation and closure of the 
autophagosome, which occurs in two ubiquitination-like reactions initiated by ATG7. The first 
reaction is conjugation of autophagy-related (ATG) proteins 5 and 12, which combine to form 
ATG16L142,46. The second reaction is lipidation of ATG4-cleaved microtubule-associated protein 
light chain 3 (LC3-I) to phosphatidylethanolamine (PE) to form LC3-II. While the exact 
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mechanism has yet to be elucidated, these reactions continue until the phagophore membrane 
is fully expanded and enclosed. The final step is fusion of the autophagosome with a lysosome, 
forming an autolysosome, to recycle the vacuolar contents into usable resources, such as 
amino acids41,42,46.  
 
 In 2004, Gutierrez et al. was the first to suggest that autophagy-induction through either 
starvation or pharmacological means, such as rapamycin, could decrease Mtb survival within a 
macrophage by overriding Mtb inhibition of phagosome-lysosome fusion47. While this study laid 
the foundation for a promising target of host-directed therapy, autophagy has recently been 
questioned as the primary mechanism of intracellular bacillary control by cells of myeloid-
lineage48. In 2015, Kimmey et al. determined that Mtb infected mice only had an increase in 
bacterial burden upon the deletion of ATG5, but not when other essential autophagy genes 
were deleted, such as ATG16L148,49. However, there is much to be understood about autophagy 
and its mechanisms. A recent review by Lindqvist et al. describes these knowledge gaps 
A B 
Figure 1.5 Classical and alternative autophagy pathways from Lindqvist, L. M., Simon, A. K. & Baehrecke, E. H. 
Current questions and possible controversies in autophagy. Cell Death Discov 1, doi:10.1038/cddiscovery.2015.36 
(2015).   
 12 
including the growing body of evidence suggesting a number of alternative mechanisms of 
autophagy (Figure 1.5 B). These mechanisms exclude what have classically been considered 
fundamental proteins, including those tested in the mouse models of Kimmey et al46. Therefore, 
as briefly suggested by its critics, autophagy may still play an important role in TB defense and 
clearance. 
Mtb Survival and Dissemination 
Mtb dissemination into neighboring cells occurs through host cell death via necrotic or 
apoptotic mechanisms, thus causing granuloma expansion (Figure 1.6)11,42. An increase in Mtb 
bacillary load is associated with necrotic cell death, allowing Mtb to spread and infect 
neighboring cells7. Also, increases in Mtb virulence are associated with extrinsic apoptotic cell 
death40,50,51. Under this condition, Mtb is able to survive within the blebbed apoptotic bodies that 
are subsequently engulfed by neighboring phagocytes, propagating the infection52. 
Figure 1.6 Mechanisms of cell death that promote bacterial dissemination from Behar, S. M., Divangahi, M. & 
Remold, H. G. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 
8, 668-674, doi:10.1038/nrmicro2387 (2010). 
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VII. Therapeutic Opportunities in Metabolic Regulation of Cell Death 
Manipulation of glucose metabolism to induce host cell intrinsic apoptosis or autophagy-
mediated cell death is a potential therapeutic intervention for inducing host-directed Mtb death 
and increasing antigen presentation. 
Relationship of Glucose Metabolism to Apoptosis and Autophagy 
Initiation of apoptosis and autophagy are metabolically signaled by the regulation of 
mTORC1 and AMPK, which are activated by alterations in ATP levels43. AMPK activation 
occurs upon ATP depletion, subsequently negatively regulating mTORC1, while promoting 
glycolysis43. Nutrient depletion along with AMPK signaling can initiate autophagy as a short-
lived survival mechanism43. However, when autophagy is insufficient for survival and ATP levels 
are chronically low, the cell will become sensitized to both intrinsic and extrinsic apoptotic 
mechanisms43,44. Prolonged inhibition of mTORC1 causes degradation of Bcl2 anti-apoptotic 
proteins, priming the cell for mitochondrial apoptosis43. Additionally, glucose deprivation will 
sensitize the cell to death-receptor induced apoptosis, increasing caspase-8 dependent 
apoptosis43.   
Metformin 
 Metformin is the most frequently prescribed type II diabetic treatment worldwide due to 
its anti-hyperglycemic effects53. Systemically, the main target of metformin is the liver where it 
inhibits gluconeogenesis while stimulating glycolysis in hepatocytes, thus decreasing hepatic 
glucose output53. Metformin’s effect is due to its partial inhibition of complex I of the ETC, 
causing a significant decrease in oxidative phosphorylation and subsequent ATP generation53. 
As described above, depletion of ATP leads to AMPK activation and potentially autophagy or 
apoptotic induction. 
 Recently, Singhal et al. have suggested metformin as an adjunct host-directed anti-TB 
therapy. It was shown to inhibit Mtb intracellular growth at concentrations of 1 mM and higher in 
human monocyte derived macrophages (hMDMs) as early as 24 hours post-infection. In these 
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experiments, it was confirmed that metformin upregulated AMPK and increased mitochondrial 
ROS for its cellular microbicidal functions. Scientists also demonstrated that hMDMs infected 
with M. bovis bacillus Calmette-Guérin (BCG), a commonly used avirulent Mtb surrogate, had 
increased autophagolysosome colocalization with BCG when treated with 2 mM metformin after 
4 hours. However, prolonged exposure to metformin did not increase mitochondrial apoptotic 
cell death54.  
 Use of metformin as a chemotherapeutic for cancer is also being explored. Many 
publications tout the antineoplastic effects associated with metformin treatment which include 
increased autophagy, apoptosis and cell cycle arrest, which demonstrate slowed rates of tumor 
growth and reduced tumor size (Figure 1.7 A)55,56. Most notable is the discovery that metformin 
increases its cytotoxic effects under a low glucose environment in a variety of cancer cell lines, 
while having little to no impact on non-cancerous cells57-61. The most common explanation for 
this paradigm is that metformin treatment increases glycolytic activity within already highly 
glycolytic cells58,60,62. Without excess extracellular glucose availability to maintain glycolytic ATP 
production in the cancerous cells, they may undergo autophagic or apoptotic cell death58,60,62. 
This suggests that the dual effect of metformin on the systemic and cellular level may function 
as a targeted therapy eliminating cells with an altered metabolic phenotype, while leaving 
physiologically healthy cells unaffected. This may also explain why metformin may be more 
effective in promoting cell death in a tumor environment where there are reduced concentrations 
of glucose compared to within the high glucose in vitro condition modeled by Singhal et al. 
2-Deoxy-D-Glucose 
 2-Deoxy-D-glucose (2DG), is a glucose analog and competitive glycolytic inhibitor whose 
radiolabeled form, 18FDG, is used in PET-CT as described above. As with glucose, when 2DG 
enters the cell, it undergoes phosphorylation by the first glycolytic enzyme, hexokinase. Unlike 
glucose, 2DG cannot be metabolized further once phosphorylated, thus inhibiting ATP 
production by glycolysis. Physiologically irrelevant levels of 2DG (above 1mM) do not activate 
 15 
AMPK or cell death, demonstrating that cells can compensate for the loss of ATP production 
from glycolysis63,64. Additionally, a 5 mM 2DG treatment in Mtb-infected murine bone marrow 
derived macrophages revealed impaired cellular bactericidal function65. It is important to note 
that these studies were performed in hyperglycemic cell culture conditions and thus may not 
have made an impact in ATP glycolytic production. However, 2DG has also been shown to 
effectively activate AMPK by increasing cellular ROS and inducing autophagy to effectively clear 
intracellular bacteria (Figure 1.7 A)45,66-70. 
 
Potential Combination Therapy: Metformin and 2DG 
 Both metformin and 2DG have been suggested as enhancers of chemotherapeutic 
agents in cancer therapy. It has also been suggested that glucose deprivation via 2DG may 
increase the efficacy of metformin and thus require lower concentrations to achieve a 
therapeutic response. This recently introduced combination therapy resulted in significant 
cellular ATP depletion in prostate cancer cells and increased AMPK-mediated cell death, 
transitioning from autophagic to an intrinsic apoptotic pathway (Figure 1.7 B)71. The benefits of 
this combined therapy are that (1) no adverse side effects have been reported with either drug 
and (2) increased efficacy of metformin via glucose depletion has decreased cellular resistance 
Figure 1.7 Metformin and 2DG mechanisms of action from Ben Sahra, I., Tanti, J. F. & Bost, F. The combination of metformin and 2-
deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 6, 670-671, doi:
10.1158/0008-5472.CAN-09-2782 (2010).    
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to chemotherapeutics rendering the drugs more effective at tumor elimination71,72. This therapy 
has slowly been gaining momentum, with several studies reporting favorable results58,61,63. 
However, this combined therapy has yet to be proposed in application to TB host-directed 
therapy. While one study demonstrated moderate increases in macrophage bactericidal 
functions using metformin (Singhal et al.) and another showed little influence with 2DG 
treatment alone (Gleeson et al.), it is possible that metformin and 2DG in combination may 
provide an enhanced synergistic effect. 2DG, as suggested by cancer treatment studies, may 
amplify the effect of metformin, which could increase anti-TB therapy efficacy leading to shorter 
and more effective TB treatment regimens. 
VIII. The Guinea Pig Model for Tuberculosis 
Since the late 19th century, guinea pigs have been the choice animal model for research 
in human bacterial infections, including TB73. Some of the similarities shared between humans 
and guinea pigs include pulmonary physiology, immunologic, hormonal and physiologic 
responses to infection, and the ability to generate a delayed-type hypersensitivity reaction after 
exposure to infection73. Additionally, guinea pigs are very susceptible to Mtb infection, which 
enables the development of a progressive infection upon implantation of a single tubercle 
bacillus, while displaying very similar lung pathology to that of humans74,75. The combination of 
the above factors makes the guinea pig an optimal animal model for the development and 
testing of new antimicrobial drugs and adjunct therapies73. Furthermore, our lab has 
demonstrated that Mtb-infected guinea pigs display non-diabetic hyperglycemia, making them 












Mycobacterium tuberculosis-infected macrophages residing in a high glucose environment have 
increased glycolytic activity that can be targeted with metformin and 2-deoxyglucose to restore 
local glucose levels and induce apoptotic cell death to enhance bacterial clearance. 
 
This hypothesis will be tested via the following aims: 
Aim 1 
Determine the effect of glucose concentration on macrophage glucose metabolism under 
activation and infection. 
Aim 2 
Determine the level of inhibition of metformin, 2-deoxy-glucose, and metformin-2-deoxy-glucose 
combined therapy on M. tuberculosis and macrophage oxidative phosphorylation and glycolysis. 
Aim 3 
Determine the effects of metformin, 2-deoxy-glucose, and metformin-2-deoxy-glucose combined 















I. Guinea Pig Bone Marrow Derived Macrophages 
Collection and Storage of Guinea Pig Bone Marrow Progenitor Cells 
Strain 13 and Hartley guinea pigs (Charles River Breeding Laboratories, Inc., 
Wilmington, MA) were anesthetized by an intramuscular injection of 25mg/kg ketamine and 
2mg/kg xylazine and euthanized using a sodium pentobarbital overdose by intraperitoneal 
injection. Following euthanasia, femurs and humerus were excised and cleared of all 
surrounding tissue using sterile gauze. Bones were soaked in 70% ethanol for one minute, 
followed by a 10 to 15 minute drying period. Sterile bone-cutting forceps removed both 
epiphyses on bones. Using a 22-gauge needle and 10 mL syringe filled with incomplete RPMI-
1640, bone marrow progenitor cells were flushed out of diaphyses. Cells were collected in a 
100x15mm petri dish and filtered through a 70 um cell strainer into a 50 mL conical tube. 
Conical tubes were centrifuged at 400 RCF for 5 minutes at room temperature. Supernatant 
was removed by aspiration and cells were resuspended in complete RPMI-1640, supplemented 
with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 ug/mL streptomycin. Cells 
were counted on a hemocytometer and viability was determined by via Trypan blue dye 
exclusion assay. Cells were resuspended at 1x107 cells/mL in freezing media composed of 85% 
FBS and 15% dimethyl sulfoxide (DMSO) for cryopreservation. Cell suspension was 
immediately divided into 1 mL aliquots, placed in methanol-containing freezing chambers, 
incubated at -80°C overnight, and transferred to the gaseous liquid nitrogen phase for long-term 
storage. 
Deriving Macrophages from Bone Marrow Progenitor Cells 
Cryopreserved cells underwent a rapid thaw by gentle agitation in a preheated 37°C 
water bath for 2 minutes. Thawed cell suspension was immediately transferred to a 50 mL 
conical tube containing 30 to 40 mL of complete RPMI-1640 as described above. Cells were 
 19 
centrifuged at 400 RCF for 5 minutes at room temperature. Supernatant was removed by 
aspiration and cells were resuspended in 20 mL of complete RPMI-1640 per thawed cryovial. A 
10 mL of cell suspension was added to a 100x15mm non-tissue-culture-treated petri dish and 
supplemented with 20 ng/mL of human recombinant macrophage-colony stimulating factor (M-
CSF; PeproTech, cat. no. 300-25). Cells differentiated over 7 days at 37°C in 5% CO2. M-CSF 
was replenished 3 days after culture start.  
Collecting and Plating Macrophages 
On day 7, non-adherent cells and complete RPMI-1640 was removed by aspiration. 
Adherent cells were washed with 5 mL of pre-warmed calcium and magnesium-free Hanks 
Balanced Salt Solution (HBSS). Each petri dish received 3 mL CellStripper nonenzymatic cell 
dissociation solution (Corning, cat. no. 25-056-CI) and incubated for 15 min at 37°C in 5% CO2. 
Remaining adherent cells were detached by scraping. Final cell suspensions were pooled in a 
50 mL conical tube. Petri dishes were washed twice with HBSS and washes were added to 
pooled cells. Cell suspensions were centrifuged at 400 RCF for 5 minutes at room temperature. 
Supernatant was removed by aspiration and cell pellet was resuspended in 3 to 5 mL complete 
RPMI-1640 media containing M-CSF. Cells were counted on a hemocytometer and viability was 
determined by Trypan blue dye exclusion assay. Cells were either plated in a 48-well sterile, 
non-tissue-culture treated plate at 300,000 cells per well or at 65,000 cells per well in Seahorse 
XFp Cell Culture miniplates (cat. no. 103025-100) pre-coated with poly-L-lysine (Sigma, cat. no. 
P4707).  
Culture Conditions 
As we have previously published, guinea pigs display increased serum glucose levels 60 
days post-Mtb infection compared to their pre-infected state. More specifically, serum glucose 
levels increase from 100 mg/dL (5mM) to 200 mg/dL (11mM). To model the two glucose 
conditions, cells were cultured in a glucose-free DMEM (ThermoFisher, cat. no. A1443001) 
containing M-CSF and supplemented with 10% dialyzed FBS, 2mM glutamine, and either 5mM 
 20 
or 11mM cell-culture grade glucose solution (Sigma, cat. no. G8769) to mimic euglycemic and 
hyperglycemic conditions, respectively, as observed in our guinea pig model. After preparation, 
all media was sterile-filtered by a 0.22um filter. Cell treatments included 1,1-dimethylbiguanide 
hydrochloride (Metformin; Sigma, cat. no. D150959) and/or 2-deoxy-D-glucose (2DG; Sigma, 
cat. no. D6134). 
II. Macrophage Infection Model 
Non-infectious Activation Model 
 A 10mg/mL suspension of zymosan A from Saccharomyces cerevisiae (Sigma, cat. no. 
Z4250) was prepared in sterile 1x phosphate buffered solution (PBS). Macrophages were 
activated by incubation with 100 ug/mL of zymosan for 4 hours at 37°C in 5% CO2. 
Mtb Infection Model 
Macrophages were incubated with Mycobacterium tuberculosis strain H37Rv (Mtb) at a 
multiplicity of infection (MOI) of 5:1 for 4 hours at 37°C in 5% CO2. Cells were washed three 
times with pre-warmed 1x PBS followed by a 1-hour incubation in complete DMEM 
supplemented with 100ug/mL gentamycin. Cells were washed once with pre-warmed 1x PBS 
and placed in final experimental media conditions.  
III. Metabolic Analysis 
We utilized two different technologies to assess cellular metabolism. The first was a high 
resolution respirometer, also known as the Oxygraph 2k (Oroboros Instruments). While this 
instrument has high sensitivity and precision, it is low throughput and cannot undergo the 
Biosafety Hazard Level 3 (BSL3) decontamination procedure. Therefore, this instrument was 
utilized for initial model development and the non-infectious activation model outside of the 
BSL3 facilities. The second technology was the 8-well extracellular flux analyzer, the Seahorse 
XFp (Seahorse Biosciences). Due to the BSL3 compatibility and high throughput capabilities, 
this instrument performed metabolic analysis on Mtb-infected cells.  
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From both instruments, we obtained two simultaneous measurements: (1) the cellular 
oxygen consumption rate and (2) the extracellular acidification rate. The oxygen consumption 
rate, or OCR, is an indirect measure of oxidative phosphorylation as this is the primary cellular 
process requiring oxygen. The extracellular acidification rate, or ECAR, is an indirect measure 
of glycolysis. The glycolytic byproducts, lactate and hydrogen ions, are secreted by the cell 
which cause a decrease in culture media pH. While the Oxygraph 2k directly measures these 
two parameters using an oxygen sensor and pH probe, the Seahorse XFp utilizes fluorophores 
to measure the excitation and emission spectra produced by changes in dissolved oxygen and 
proton concentrations. 
 To test the metabolic parameters of a cell sample, we added a series of substrates that 
systematically shut down or promoted different components of mitochondrial respiration or 
glycolysis. When the cell samples are first inserted into the Oxygraph 2k or the Seahorse XFp, 
they are suspended in a non-buffered Dulbecco's Modified Eagle's Medium Base, 
supplemented with 10mM glucose, 2mM pyruvate, and 2mM L-glutamine, 7.4 pH. Here, OCR 
and ECAR measurements provide the cellular metabolic baseline. Next, 0.5 uM of rotenone and 
antimycin A, inhibitors of complexes I and III of the electron transport chain, are added to stop 
mitochondrial respiration which causes a decrease in OCR. Here, ECAR either remains stable if 
cells are primarily glycolytic or will increase, demarcating a shift in metabolism from oxidative 
phosphorylation to glycolysis for ATP generation. The second substrate added is 50mM 2DG, a 
competitive inhibitor of glucose metabolism. With 2DG entering the cell at five times the rate of 
glucose, ATP production via glycolysis stops, thus decreasing cellular ECAR. Both substrate 
injections enable the calculation of cellular respiration and glycolysis. 
IV. Fluorescent and Colorimetric Assays 
Lactate Production Assay 
We used the Picoprobe L-Lactate Assay Kit by Abcam (cat. no. ab169557) as a 
secondary measure of cellular glycolytic activity. Here, L-Lactate, the main stereoisomer 
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produced by lactate dehydrogenase, is oxidized to form an intermediate that reacts with a probe 
to fluoresce. To begin, Lactate Enzyme and Substrate Mixes were reconstituted per kit 
instructions followed by the dilution of the 10mM Lactate Standard to 25uM to produce a 
standard curve. Lactate standards and 1:400 diluted cell sample supernatants were added to a 
black, clear-bottom 96-well microplate in duplicate. Next, reaction and background control mixes 
were added. Using the Gen5™ Reader Control and Data Analysis Software, the microplate was 
programmed 60incubate at room temperature for 30 minutes within the Synergy 2 Multi-Mode 
Reader by BioTek, followed by fluorescent measurement using the 530/25 nm and 590/35 nm 
excitation and emission filters respectively. After all values were obtained, the 0 pmol lactate 
standard value was subtracted from all other standard and sample values. If the background 
control was significantly, it was also subtracted from the sample readings. A lactate standard 
curve was generated in GraphPad Prism and sample concentration values were calculated per 
kit instructions. 
Minimum Inhibitory Concentrations of 2DG and Metformin Treatment on Mtb Growth 
 A frozen aliquot of H37Rv Mtb was brought to room temperature and resuspended in 10 
mL of 7H9 broth, supplemented with 0.05% Tween 80 and 10% OADC. Mtb incubated for 48 
hours at 37°C and suspension turbidity was matched to 1/25 of a McFarland no. 1 turbidity 
standard (OD 0.0156nm). Dilutions (1:2) of 2DG and Metformin were performed in a sterile 96-
well plate in 7H9 media, or complete DMEM containing 5mM or 11mM glucose concentrations. 
Final well concentrations of 2DG ranged from 8.75 mM to 0 mM, while metformin concentrations 
ranged from 3 mM to 0 mM. Diluted Mtb (100 uL) was added to all wells. Plate was sealed with 
parafilm and incubated for 5 days at 37°C. On day 5, 50 uL of a 1:1 dilution of alamar blue and 
10% Tween 80 was added to all wells and plate was resealed. After an additional 24 hour 
incubation at 37°C, the plates were read in the Synergy 2 Multi-Mode Reader at OD 570nm and 
600nm to determine levels of bacterial growth. 
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V. Survival Assays 
Trypan Blue Exclusion Assay 
 Complete media was removed from macrophage cultures and saved in a 15 mL conical 
tube. Next, macrophages were rinsed with 500 uL of 1x PBS and washes were combined with 
media in conical tube. CellStripper nonenzymatic cell dissociation solution was added to wells 
(250 uL) and incubated for 15 minutes at 37°C in 5% CO2. Macrophages were detached by 
gentle scraping with a 1 mL syringe plunger. Cell suspension was combined with media and 
washes in conical tube. Wells were washed twice with 1 mL complete DMEM and added to 
conical tube. Tubes were centrifuged at 400RCF for 5 minutes at room temperature. 
Supernatant was decanted and cell pellets were resuspended in 500 uL complete DMEM. Cell 
suspension (10 uL) was combined with 10 uL of 0.4% Trypan Blue Solution. The combined 
solution was inserted onto a hemocytometer (10 uL) and cells including and excluding Trypan 
blue were quantified under the microscope. 
Autophagy/Apoptosis/Necrosis Assay 
 The following reagents were used in this assay: monodansylcadaverine (MDC; Sigma, 
cat. no. 30432), FAM FLICA™ Caspase 3 & 7 reagent (Immunochemistry, cat. No. 94), 
SYTOX® AADvanced™ Dead Cell Stain (ThermoFisher, cat. no. C10427), and APC Annexin V 
(Biolegend, cat. no. 640920). To begin, 0.05mM MDC and caspase 3 and 7 reagent were added 
to cell cultures followed by a 1 hour incubation at 37°C in 5% CO2. Next, cell cultures were 
detached from 48-well plates using CellStripper as described above, washed twice in 1x 
apoptosis wash buffer, and resuspended in 200 uL 1x annexin binding buffer containing 1:20 
APC Annexin V. Tubes incubated for 15 minutes at room temperature. 1 uM of SYTOX® 
AADvanced™ Dead Cell Stain was added for the last 5 minutes of the APC Annexin V staining 
duration. Samples were immediately placed on ice prior to analysis. Cells treated with 8 uM 
rapamycin, 20 uM camptothecin, and 0.005% Triton x 100 for 12 hours served as positive 
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controls for autophagy, apoptosis, and necrosis respectively. Flow cytometric analysis was 
performed on the BD™ LSR II using BD FACSDiva™ software. 
Mtb Survival Assay 
Macrophages were detached from the 48-well plate using CellStripper nonenzymatic cell 
dissociation solution as described above and counted using Trypan blue dye exclusion assay. 
Once quantified, cells were lysed in 0.1% Triton X 100 at 37°C for 10 minutes. 1:10 serial 
dilutions were made in sterile 1x PBS and plated on 7H11 agar plates, supplemented with 
OADC, Carbenicillin, and Cyclohexamide. Plates incubated at 37°C and colony-forming units 
were quantified after 21 days. 
VI. Statistical Analysis 
 GraphPad Prism 7 and SAS 9.4 software were used for statistical analysis with an alpha 
equal to 0.05. A two-way factor analysis of variance (ANOVA) was performed on all data sets to 
determine differences between cellular infection and treatment-status and differences within 
these groups over time. A Tukey’s range test was used to determine statistical differences 
among treatment groups at a specific time point and within each treatment group over time. 
Dunnett’s test was employed for dose response curves and Trypan blue dye exclusion assays 
for comparison of treatment groups to an untreated control. Use of a three-way factor ANOVA 
determined statistical significance between 100mg/dL and 200mg/dL glucose conditions on 













Aim 1: Determine the effect of glucose concentration on macrophage glucose metabolism 
under activation and infection. 
Using the non-infectious activation and Mtb infection models, basal respiration and 
glycolysis were assessed 4 hours after stimulation using the Oxygraph 2k and Seahorse XFp 
analysis (Figure 2.1). Zymosan A stimulated GPBMDMs increased basal respiration under a 
100mg/dL glucose condition (P<0.0002), while slightly elevating basal respiration in a 200mg/dL 
glucose condition (Fig 2.1 A). Glycolytic activity increased under both glucose conditions after 4 






Figure 2.1 Macrophage activation and infection increases basal oxygen consumption and 
glycolytic rate. GPBMDM basal respiration under (A) zymosan A stimulation or (B) Mtb infection. 
GPBMDM glycolysis under (C) zymosan A stimulation or (B) Mtb infection. Data is expressed as (A) 
O2 flux per volume in pmol/(s*mL) per 10
6
 cells ± standard deviation (SD), (B) oxygen consumption 
rate (OCR) in pmol/min per 65,000 cells ± SD, (C) proton flux in pmol/(s*mL) per 10
6
 cells ± SD, and 
(D) extracellular acidification rate (ECAR) in mpH/min per 65,000 cells ± SD. (A and C) n=7 in 
uninfected cells and n=5 in zymosan A stimulated cells, (B and D) n=6 in uninfected cells and n=6 in 
Mtb infected cells. * and # =P≤ 0.05, ** =P≤ 0.01, ***=P≤ 0.001, ****=P≤ 0.0001.  
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Mtb-infected GPBMDMs displayed a similar metabolic profile to zymosan A stimulated 
GPBMDMs (Fig 2.1 B and D). Under a 100mg/dL glucose condition, Mtb-infection increased 
GPBMDM basal respiration (P<0.0113) (Fig 2.1 B). In uninfected GPBMDMs, exposure to a 
200mg/dL glucose environment from a 100mg/dL glucose environment increases basal 
respiration (P<0.0254) (Fig 2.1 B). Mtb-infected GPBMDMs increase their glycolytic activity 
compared to uninfected GPBMDMs (P<0.0001, P<0.0052) (Fig 2.1 D). These data demonstrate 
that macrophage activation and infection increase basal respiration and glycolytic rates 
compared to uninfected macrophages, and that a high glucose environment impairs the 
respiratory response to activation or infection.  
Uninfected and Mtb-infected GPBMDMs basal respiration and glycolytic activity were 
analyzed over 72 hours using the Seahorse XFp and lactate production assay. In 100mg/dL 
glucose conditions, infected GPBMDMs had increased basal respiration compared to uninfected 
GPBMDMs beginning 4 hours post-infection  (P<0.0113) and lasting for at least 72 hours (Fig 
2.2 A). Under 200mg/dL glucose conditions, infected GPBMDM basal respiration remained 
similar to uninfected GPBMDMs, except at 48 hours post-infection where it peaked similarly to 4 
hours post-infection (P<0.0122) (Fig 2.2 B). Significant decreases in basal respiration were 
noted in both uninfected and infected GPBMDMs under a 200mg/dL glucose condition over time 
(P<0.0001) (Fig 2.2 B). Under both 100 and 200mg/dL glucose conditions, glycolytic activity 
peaked 48 hours post-infection (200mg/dL =P<0.0004) and declined by 72 hours (100mg/dL 
=P<0.003, 200mg/dL =P<0.0001) (Fig 2.2 C and D). However, glycolytic activity in infected 
cells under a 100mg/dL glucose condition remained elevated after 48 hours, while those under 
a 200mg/dL glucose condition did not (Fig 2.2 C and D).  
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A lactate production assay was used to validate cellular glycolytic activity. Overall, 
infected GPBMDMs produced more lactate than uninfected GPBMDMs (Fig 2.3). Lactate 
accumulated more rapidly in infected GPBMDMs under a 100mg/dL glucose condition than 
those in a 200mg/dL glucose condition. This was most notable 48 hours post-infection where 
infected GPBMDMs under a 100mg/dL glucose condition had significantly greater lactate 
accumulation than those under a 200mg/dL glucose condition (P<0.0319) (Fig 2.3). Compared 
to uninfected GPBMDMs, infected GPBMDMs had significantly more lactate accumulation 48 
and 72 hours post-infection under a 100mg/dL glucose condition (P<0.0003 and P<0.0081) (Fig 
2.3 A). In a 200mg/dL glucose condition, lactate accumulation in infected GPBMDMs was also 




Figure 2.2 Mtb-infected macrophages have different metabolic profiles under normal 
and high glucose conditions. GPBMDM basal respiration in (A) 100mg/dL and (B) 200mg/dL 
glucose conditions. GPBMDM glycolysis in (C) 100mg/dL and (D) 200mg/dL glucose conditions. Data 
is expressed as (A and B) OCR in pmol/min per 65,000 cells ± SD, (C and D) ECAR in mpH/min per 
65,000 cells ± SD. (A and C) n=6, 2, 3, and 3 in uninfected cells and n=8, 4, 3, and 3 in infected cells, 
(B and D) n=6, 2, 3, and 2 in uninfected cells and n=6, 3, 3, and 3 in infected cells at specified time 
points. *=P≤ 0.05, ** =P≤ 0.01, ***=P≤ 0.001, ****=P≤ 0.0001.  
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B). These data suggest that GPBMDM glycolytic responses to infection are also impaired under 
a high glucose environment. 
 
Aim 2: Determine the level of inhibition of metformin, 2-deoxy-glucose, and metformin-2-deoxy-
glucose combined therapy on M. tuberculosis and macrophage oxidative phosphorylation and 
glycolysis. 
After infecting GPBMDMs, metformin and/or 2DG were added to cell cultures. According 
to pharmacokinetic/pharmacodynamic studies, metformin in blood sera reaches a peak 
concentration of 12uM, while 2DG concentration peaks at 700uM76,77. Concentrations above 
and below these blood sera levels were chosen for formation of dose response curves in 
infected GPBMDMs. Dose response curves demonstrated that metformin treatment alone 
decreases basal respiration and increases glycolysis in a dose-dependent manner after 24 
hours (Fig 2.4 A and B). 1.2mM metformin was the only dose to have statistically significant 
inhibition of basal respiration after 4 hours of treatment (P<0.0295) (Fig 2.4 A). 2DG treatment 
decreased basal respiration and glycolysis dose-dependently after 4 and 24 hours (Fig 2.4 C 
and D). While there were no statistically significantly decreases in basal respiration, glycolysis 
decreased with 2DG treatment after 4 hours starting at 700uM (P<0.0001) (Fig 2.4 D). 3.5mM, 
7mM, and 35mM concentrations of 2DG also demonstrated statistically significant decreases in 
glycolysis after 4 hours of treatment (P<0.0277, P<0.0456, and P<0.0148) (Fig 2.4 D).  
A B 
Figure 2.3 Mtb-infected macrophages have different levels of lactate accumulation. 
GPBMDM lactate production in (A) 100mg/dL and (B) 200mg/dL glucose conditions. Data is 
expressed as pmol/uL lactate ± SD. n= 3, 3, and 4 in uninfected cells and n=3, 3, and 3 in infected 









Figure 2.4 Metformin, 2DG, and Metformin-2DG dose response curves 4 and 24 hours post-
infection and treatment in a 100mg/dL glucose condition. (A) Basal respiration and (B) glycolysis in 
uninfected (n=6) and infected GPBMDMs after metformin treatment at doses 0mM (n=8), 2.4uM (n=3), 
12uM (n=4), 60uM (n=3), 120uM (n=3), 600uM (n=3), and 1.2mM (n=4). (C) Basal respiration and (D) 
glycolysis in uninfected (n=6) and infected GPBMDMs after 2DG treatment at doses 0mM (n=8), 70uM 
(n=3), 140uM (n=3), 700uM (n=5), 3.5mM (n=3), 7mM (n=3), and 35mM (n=3). (E) Basal respiration and 
(F) glycolysis in uninfected (n=6) and infected GPBMDMs (n=8) after treatment with 700uM 2DG and 
metformin doses 0mM (n=5), 2.4uM (n=3), 60uM (n=3), 120uM (n=3), 600uM (n=3), and 1.2mM (n=3). 
Data is expressed in (A, C, and E) OCR in pmol/min per 65,000 cells ± SD and (B, D, and F) ECAR in 
mpH/min per 65,000 cells ± SD. *=P≤ 0.05, ** =P≤ 0.01, ***=P≤ 0.001, ****=P≤ 0.0001. 
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Using the physiologically relevant 700uM 2DG dose, concentrations of metformin tested 
singly were also tested in combination to determine the optimal dual treatment for inhibition of 
both basal respiration and glycolysis (Fig 2.4 E and F). Overall, combined metformin and 2DG 
treatment decreased cellular basal respiration after 24 hours more effectively than singly treated 
GPBMDMs (Fig 2.4 E). After 4 hours, 2.4uM, 60uM, 120uM, 600uM, and 1.2mM metformin 
doses in combination with 2DG significantly inhibited basal respiration (P<0.0069, P<0.0079, 
P<0.0031, P<0.0014, and P<0.0058) (Fig 2.4 E). After 24 hours, 600uM metformin in 
combination with 700uM 2DG was most effective at inhibiting basal respiration (P>0.0357) (Fig 
2.4 E). 2.4uM, 12uM, and 1.2mM metformin doses in combination with 2DG also significantly 
inhibited glycolysis after 4 hours (P<0.0316, P<0.0001, and P<0.005) (Fig 2.4 F). However, 
after 24 hours 2DG inhibited glycolysis regardless of metformin concentration (Fig 2.4 F). 
Collectively, the combination of 600uM metformin and 700uM 2DG was most effective at 
inhibiting both basal respiration and glycolysis in infected GPBMDM. While this dose of 
metformin is greater than the physiologic blood sera maximum concentration, it is less than half 
the concentration typically used in metformin in vitro studies and well below the concentration 
needed to cause metformin-associated lactic acidosis54,60,71.  
Three metformin and 2DG MICs were performed using serial dilutions of each 
compound. Maximal metformin and 2DG concentrations were 3mM and 8.75mM, respectively. 
Mtb growth was not inhibited by either compound, but was inhibited by its growth media. 7H9 
broth promoted bacterial growth, while DMEM inhibited bacterial growth regardless of metformin 
and/or 2DG being present (Fig 2.5 A). Metabolic analysis on 2.5x106 CFU of Mtb within DMEM 
media (over 7 times the amount used to infect GPBMDMs) revealed very little basal respiration 
and glycolytic activity (Fig 2.5 B). These results indicate that Mtb growth is unaffected by 
metformin and/or 2DG treatment and that extracellular Mtb metabolic activity did not confound 
the GPBMDM metabolic analysis. 
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 Uninfected and infected GPBMDMs were treated with 600uM metformin and 700uM 
2DG under 100 and 200mg/dL glucose conditions. Significant inhibition of basal respiration in 
uninfected GPBMDMs occurred 4 hours after metformin-2DG treatment in both glucose 
conditions (P<0.0333, P<0.0001), and also occurred 24 hours after treatment in the 200mg/dL 
glucose condition (P<0.0068) (Fig 2.6 A and B). In uninfected GPBMDMs, metformin-2DG 
treatment became ineffective at inhibiting basal respiration after 24 hours (Fig 2.6 A and B). 
Under a 100mg/dL glucose condition, metformin-2DG treatment of infected GPBMDMs 
suppressed basal respiration as early as 4 hours after treatment and was sustained for 72 hours 
(P<0.0025, P<0.0484) (Fig 2.6 C). Under a 200mg/dL glucose condition, metformin-2DG 
treatment did not effectively suppress basal respiration until 48 hours after treatment (P<0.0002), 
but caused an overall decrease in basal respiration over 72 hours (P<0.0001) (Fig 2.6 D). 









Figure 2.5 Mtb growth and metabolism are not affected by metformin, 2DG, or metformin-2DG 
combined treatments. (A) Mtb growth in 7H9 broth or DMEM media containing 100 or 200mg/dL 
glucose, treated with metformin and/or 2DG. (B) Basal respiration and glycolysis of 2.5x10
6
 CFU Mtb 
after 4 and 24 hours of metformin and/or 2DG treatment (n=3). 
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glucose condition after 4 and 24 hours at inhibiting basal respiration (P<0.0491, P<0.0001) (Fig 
2.6 C and D). These data suggest that metformin-2DG treatment is most effective at 
suppressing the basal respiration of infected cells over time, particularly in a 100mg/dL glucose 
condition, while having little sustained effects on uninfected cells. 
 
 Uninfected GPBMDMs under a 100mg/dL glucose condition, metformin-2DG treatment 
inhibited glycolysis after 4 hours post-treatment (P<0.0333) (Fig 2.7 A). Under a 200mg/dL 
glucose condition, metformin-2DG treatment inhibited glycolysis after 4 and 24 hours post-
treatment in uninfected GPBMDMs (P<0.0001, P<0.0068) (Fig 2.7 B). Under both glucose 
conditions, metformin-2DG treatment in uninfected GPBMDMs became ineffective at inhibiting 
glycolysis after 24 hours (Fig 2.7 A and B). Metformin-2DG treatment of infected GPBMDMs 
inhibited glycolysis starting 24 hours post-treatment in a 100mg/dL glucose condition 




Figure 2.6 Metformin-2DG combined treatment effectively suppresses basal respiration in 
infected GPBMDMs over time. Basal respiration of uninfected GPBMDMs with and without 
metformin-2DG combined treatment in (A) 100mg/dL and (B) 200mg/dL glucose conditions. Basal 
respiration of infected GPBMDMs with and without metformin-2DG combined treatment in (C) 
100mg/dL and (D) 200mg/dL glucose conditions. Data is expressed in OCR pmol/min per 65,000 
cells ± SD. (A and B) n=6, 2, 3, and 3 in untreated cells, n=3 for all treated cell time points. (C and 
D) n=8, 4, 3, and 3 in untreated cells and n=3 in all treated cells at specified time points. *=P≤ 
0.05, ** =P≤ 0.01, ***=P≤ 0.001, ****=P≤ 0.0001. 
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under a 100mg/dL glucose condition (P<0.03, P<0.0145), with an overall inhibition occurring 
between 4 and 72 hours (P<0.0001) (Fig 2.7 C). Under a 200mg/dL glucose condition, 
glycolytic inhibition occurred 4 and 48 hours post-treatment (P<0.02, P<0.0001), with an overall 
increase in treatment efficacy over 72 hours (P<0.0025) (Fig 2.7 D). Between glucose 
conditions, metformin-2DG treatment is most effective under a 100mg/dL glucose condition as 
early as 24 hours post-treatment (P<0.0032), while under a 200mg/L glucose condition, 
treatment efficacy is delayed 48 hours (P<0.0001) (Fig 2.7 C and D). This data indicates that 
under a 100mg/dL glucose condition, metformin-2DG glycolytic inhibition is most effective due 
to its rapid and prolonged metabolic suppression. This data reiterates that metformin-2DG 
treatment becomes ineffective in uninfected GPBMDMs after 24 hours. 
 
 Under both glucose conditions, cellular lactate production increases when singly treated 




Figure 2.7 Metformin-2DG combined treatment effectively suppresses glycolysis in infected 
GPBMDMs over time. Glycolysis of uninfected GPBMDMs with and without metformin-2DG 
combined treatment in (A) 100mg/dL and (B) 200mg/dL glucose conditions. Glycolysis of infected 
GPBMDMs with and without metformin-2DG combined treatment in (C) 100mg/dL and (D) 
200mg/dL glucose conditions. Data is expressed in ECAR mpH/min per 65,000 cells ± SD. (A and 
B) n=6, 2, 3, and 3 in untreated cells and n=3 for all treated cell time points. (C and D) n=8, 4, 3, 
and 3 in untreated cells and n=3 for all treated cells at specified time points. *=P≤ 0.05, ** =P≤ 0.01, 
***=P≤ 0.001, ****=P≤ 0.0001. 
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to untreated GPBMDMs (P<0.0001) (Fig 2.8). Between 24 and 72 hours metformin-2DG treated 
GPBMDMs increase lactate production under a 200mg/dL glucose condition (P<0.0087), while 
lactate production remained inhibited under a 100mg/dL glucose condition (Fig 2.8). Statistical 
significance between the two glucose conditions for metformin-2DG treated cells after 72 hours 
is P<0.0033. This data confirms that glycolytic inhibition most effectively occurs under a 
100mg/dL glucose condition using a combined treatment. 
 
Aim 3: Determine the effects of metformin, 2-deoxy-glucose, and metformin-2-deoxy-glucose 
combined therapy on M. tuberculosis and macrophage viability. 
CFUs were plated from infected untreated, metformin treated, 2DG treated, and 
metformin-2DG treated GPBMDMs. In a 100mg/dL glucose condition, CFUs increased over 
time in all treatment groups over the first 48 hours, except in metformin-2DG treated GPBMDMs 
(Fig 2.9 A). After 24 hours, the combined treatment decreased CFU counts, restoring them to 4 
hour baseline levels (Fig 2.9 A). In a 200mg/dL glucose condition, baseline CFU counts began 
lower than in the 100mg/dL glucose condition (Fig 2.9 A and B). However, after 24 hours, 
CFUs from 2DG treated cells surpassed those observed in the lower glucose condition and 
outgrew all other sample CFUs by 48 hours (Fig 2.9 B). By 72 hours, CFUs from all treatment 
groups in the 200mg/dL glucose condition were similar to those in the 100mg/dL glucose 
A B 
Figure 2.8 Metformin-2DG combined treatment inhibits lactate production more effectively in 
normal versus high glucose conditions. Lactate production in uninfected (n=3), infected (n=3), and 
infected-metformin (n=3), 2DG (n=3), and metformin-2DG treated GPBMDMs (n=3) in (A) 100mg/dL 
and (B) 200mg/dL glucose conditions. Data is expressed in pmol/uL ± SD. *=P≤ 0.05, ** =P≤ 0.01, 
***=P≤ 0.001, ****=P≤ 0.0001.  
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condition (Fig 2.9 A and B). In the higher glucose condition, the metformin-2DG combined 
treatment was less effective at inhibiting bacterial growth than in the lower glucose condition. 
While bacterial growth was suppressed compared to the other treatment groups, it was not 
inhibited as it was in the lower glucose condition (Fig 2.9 A and B). This CFU data suggests 
that combination treatment enhances GPBMDM bactericidal capacity under a 100mg/dL versus 
a 200mg/dL glucose condition. 
 
  
 Under both glucose conditions, 2DG treatment alone significantly decreased cell viability 
over 72 hours (P<0.0001), while metformin treatment alone had little effect on cell viability 
compared to untreated GPBMDMs (Fig 2.10). Under a 200mg/dL glucose condition, infection 
alone caused a significant decrease in cell viability from 24 to 72 hours (P<0.0411) (Fig 2.10 B). 
Metformin treatment in combination with 2DG protected GPBMDM cell viability compared to 
2DG treatment alone. This data suggests 2DG singly treated GPBMDMs may have a different 
mechanism of cell death compared to metformin-2DG treated cells, which may be the reason for 
the notable decrease in bacterial CFUs. 
A 
Figure 2.9 Metformin-2DG combined treatment decreases bacterial growth more 
effectively than metformin or 2DG treatment alone. Mtb CFUs from infected (n=4), and 
infected-metformin (n=3), 2DG (n=3), and metformin-2DG treated GPBMDMs (n=4) in (A) 





To investigate potential mechanisms of cell death, flow cytometric analysis was 
performed. First we assessed general stages of cell death, which included live, apoptotic, and 
necrotic according to negative and positive markers for annexin V and SYTOX® AADvanced™ 
Dead Cell Stain (Fig 2.11). After 24 hours both 2DG and metformin-2DG had an increased 
percent of cells undergoing apoptosis in both 100 and 200mg/dL glucose conditions (Fig 2.11 A 
and B). By 48 hours, the percent of apoptosis was approximately 40 percent greater in 2DG 
and metformin-2DG treated cells compared to uninfected, infected, and metformin treated cells 
(Fig 2.11 C and D). By 72 hours, apoptosis in 2DG and metformin-2DG treated cells increased 
by an additional 10 percent compared to all other conditions (Fig 2.11 E and F). 24, 48, and 72 
hour time points did not reveal significant differences in cell populations between glucose 
conditions (Fig 2.11). While necrotic cell populations were present, the majority was likely lost in 
the cell staining process. 
A B 
Figure 2.10 Metformin-2DG combined treatment inhibits lactate production more 
effectively in normal versus high glucose conditions. Cell viability in uninfected, infected, 
and infected-metformin, 2DG, and metformin-2DG treated GPBMDMs in (A) 100mg/dL and 
(B) 200mg/dL glucose conditions. Data is expressed in percent live ± standard error of the 
mean (SEM). (A) n=4, 3, and 7 in uninfected cells, n=7, 7, and 10 in infected cells, n=3, 3, 
and 3 in infected-metformin and 2DG singly treated cells, n=3, 5, and 6 in infected-
metformin-2DG treated cells for each time point. (B) n=5, 3, and 7 in uninfected cells, n=8, 5, 
and 10 in infected cells, n=3, 3, and 3 in infected-metformin and 2DG singly treated cells, 
n=6, 5, and 6 in infected-metformin-2DG treated cells for each time point. *=P≤ 0.05, ** =P≤ 
0.01, ****=P≤ 0.0001.  
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 Next, we discerned the various stages of apoptosis and whether they were caspase 3 
and 7 dependent and independent pathways (Fig 2.12). At 24 hours, cells in a caspase 3 and 7 
independent state predominated 2DG and metformin-2DG treated populations (Fig 2.12 A and 
B). This trend continued through 48 and 72 hours post-treatment (Fig 2.12 C-F). There were 
differences in apoptotic cell stages and caspase dependence between normal and high glucose 







Figure 2.11 2DG and Metformin-2DG combined treatment increase apoptotic cell death 
in Mtb-infected GPBMDMs after 48 hours. Percent live, apoptotic, and necrotic (A and B) 
24 hours, (C and D) 48 hours, and (E and F) 72 hours post-treatment under (A, C, and E) 
100 mg/dL and (B, D, and F) 200mg/dL glucose conditions. Data is expressed in percent of 
total single cells ± SEM. (A-D) n=2, (E-F) n=3.  
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hours, the 100mg/dL glucose condition had an overall lower percent of caspase-dependent 
apoptosis, while the 200mg/dL glucose condition had more caspase-dependent apoptosis, 
particularly in the early apoptotic phase (Fig 2.12 A and B). Infected cells without treatment had 
a greater percent of cells in the mid-apoptotic phase at 24 hours in the normal versus high 
glucose condition (Fig 2.12 A and B). Starting at 48 hours, 2DG and metformin-2DG treated 








Figure 2.12 2DG and Metformin-2DG treatment increase cells in their mid-apoptotic 
stage of cell death in Mtb-infected GPBMDMs. Percent of early, mid and late apoptotic 
cells that are caspase positive or negative (A and B) 24 hours, (C and D) 48 hours, and (E 
and F) 72 hours post-treatment under (A, C, and E) 100 mg/dL and (B, D, and F) 200mg/dL 
glucose conditions. Data is expressed in percent of total single cells ± SEM. (A-D) n=2, (E-F) 
n=3.  
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 Autophagy was assessed with the autophagosome marker monodansylcadaverine in 
live, apoptotic, and necrotic cell populations within each condition over time (Fig 2.13). At 24 
hours, similar profiles were noted between glucose conditions and among treatment groups (Fig 
2.13 A and B). At 48 and 72 hours, the normal glucose condition had 25 percent less 
autophagosome formation than the high glucose condition, with the most extensive inhibition 
with 2DG and metformin-2DG treatments (Fig 2.13 C-F).  However, 2DG treated cells had 
approximately 10 percent more autophagy than metformin-2DG treated cells (Fig 2.13 C and 
D). Collectively this data suggests that 2DG and metformin-2DG treatments generate similar 
mechanisms of cell death and similar autophagy trends, but demonstrate opposite trends in 
bacterial CFUs. This suggests that bacterial death associated with metformin-2DG treatment is 















Figure 2.13 2DG and Metformin-2DG treatment inhibited baseline levels of autophagy 
in Mtb-infected GPBMDMs. Percent of live, mid and late apoptotic, and necrotic cells (A 
and B) 24 hours, (C and D) 48 hours, and (E and F) 72 hours post-treatment under (A, C, 
and E) 100 mg/dL and (B, D, and F) 200mg/dL glucose conditions. Data is expressed in 






With MDR TB cases on the rise and lags in antimicrobial drug development, it is 
imperative to explore alternative methods of treatment such as host-directed adjunct therapies. 
One therapeutic opportunity is to reduce chronic non-diabetic hyperglycemia associated with 
Mtb infection. Metformin, an anti-diabetic drug, acts on both cellular and systemic levels by 
stimulating glycolysis within the liver and other cell types via partial inhibition of oxidative 
phosphorylation, subsequently decreasing blood glucose levels. Treatment of infected M1 
macrophages with metformin increases cellular metabolic stress by increasing glycolysis in 
already glycolytic cells. The addition of 2DG, a glycolytic inhibitor, in combination with metformin 
further exacerbates this metabolic stress, which can favorably induce mitochondrial-driven 
apoptotic cell death. This mechanism of cell death can increase Mtb-clearance and antigen 
presentation, enabling the activation of adaptive immune responses. From this information we 
hypothesized that bacterial survival is aided by glycolysis-dependent macrophages, which can 
be targeted using a combination of metformin and 2DG to strengthen host immune responses. 
The first aim was to determine the effect of normal versus high glucose concentrations 
on glucose metabolism in activated macrophages. Consistent with other studies, we confirmed 
that activated and Mtb-infected macrophages rely more on glycolysis than uninfected 
macrophages17,18,23,26,65. In addition to increased glycolysis, we observed that Mtb-infected 
macrophages also increase their basal respiration, both peaking after 48 hours. This 
simultaneous increase likely indicates pro-inflammatory, bactericidal macrophage activation 
where glycolysis is upregulated to generate ATP and oxygen consumption increases for 
mitochondrial ROS production19. However, we also observed that metabolic responses to 
infection are impaired under a high glucose environment. Upon infection, basal respiration did 
not increase from a quiescent macrophage state and glycolytic responses were delayed. This 
aligns with past studies concluding that cells under a high glucose condition have an impaired 
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pro-inflammatory responses to infection, such as glycolytic upregulation and mitochondrial ROS 
production35-37. Macrophages infected under a high glucose condition also demonstrated lower 
initial bacterial CFUs compared to macrophages infected under a normal glucose environment, 
which may confirm previous studies suggesting impaired phagocytic capabilities under 
hyperglycemia35. Data gathered under this aim suggests that a high glucose environment 
impairs macrophage responses to infection by generating insufficient metabolic shifts to perform 
effective bactericidal functions. 
Next, we determined the level of inhibition of metformin, 2DG, and combined metformin-
2DG treatment on the altered metabolism of Mtb-infected macrophages. Aligning with their 
proposed mechanisms of action, metformin treatment increased while 2DG treatment inhibited 
glycolytic activity64. In combination, metformin-2DG treatment partially inhibited glycolysis 
compared to untreated cells, indicating that metformin moderates the inhibitory mechanism of 
2DG. This is likely due to the increased glycolytic activity by metformin offsetting the competitive 
inhibition of 2DG on glucose. Over 72 hours, metformin-2DG treatment provided sustained 
inhibition of basal respiration and glycolytic activity in Mtb-infected macrophages. The 
suppression of both rates may inhibit both mitochondrial ROS production and glycolytic 
dependence on ATP generation, rendering the cell incapable of performing its normal 
physiologic responses to infection, while simultaneously placing metabolic stress on the cell. 
However in uninfected macrophages, metformin-2DG treatment became ineffective after 48 
hours, restoring both respiratory and glycolytic rates to an uninfected, untreated state. This 
indicates that metformin-2DG treatment is most effective at targeting cells with an upregulated, 
altered metabolism, while maintaining the metabolic stability in those unaffected. When 
assessed under a high glucose condition, inhibition of basal respiration and glycolysis by 
metformin-2DG treatment were delayed in Mtb-infected macrophages demonstrating that 
metformin-2DG treatment is most effective in activated cells that are highly dependent on 
glycolysis for energy production. These observations suggest that metformin-2DG treatment 
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may be an ideal therapy for predominantly targeting the metabolic activity of Mtb-infected versus 
uninfected macrophages.  
 The final aim was to determine the effects of metformin, 2DG and metformin-2DG 
treatment on Mtb and macrophage viability. As confirmed by Gleeson et al, 2DG treatment 
increased bacterial viability, while metformin-2DG treatment decreased bacterial viability over 
time65. This data suggests that the cell death associated with metformin-2DG treatment can 
clear bacterial infections, whereas macrophage death by 2DG treatment alone is ineffective, 
enabling bacterial survival. When assessed via Trypan blue dye exclusion assay, macrophage 
viability was not dependent on glucose condition, meaning that all treatments produced similar 
responses to cell death regardless of normal or high glucose conditions. While metformin had 
little effect on cell viability, 2DG potentiated cell death over 72 hours. However, in combination, 
metformin was protective against 2DG-related cell death. To contrast these results, flow 
cytometry revealed similar cell death trends and populations between 2DG and metformin-2DG 
treatments. These groups had increased apoptotic cell death and inhibited autophagy over time. 
A potential explanation for this unexpected result is that the inclusion of metformin with 2DG 
may activate other survival or death pathways, including an alternate method of apoptosis. 
While the exact mechanism has yet to be elucidated, it is possible that the metformin-2DG 
treatment may be enabling antigen presentation through the observed decrease in bacterial 
survival.  
While glucose condition had little effect on macrophage viability, it did make a difference 
in bacterial survival and replication. Initially, bacterial CFUs were lower under the high glucose 
condition compared to the normal glucose condition. However, over time bacterial growth under 
the high glucose environment surpassed those under the normal glucose condition. This 
suggests that impaired macrophage responses to infection due to high glucose concentrations 
favors bacterial survival. Despite increasing bacterial survival, metformin-2DG treatment was 
capable of curtailing bacterial growth over the 72-hour time span demonstrating that even under 
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high glucose conditions, metformin-2DG treatment can restore macrophage responses to 
infection. 
 Collectively, we can conclude that bacterial survival is not dependent on macrophage 
glycolysis as demonstrated by the increase in CFUs in 2DG-only treated cells. However, the use 
of both metformin and 2DG in combination was effective under both normal and high glucose 
conditions at controlling bacterial growth. Additionally, metformin-2DG treatment targets cells 
with an upregulated glycolytic glucose metabolism, and increasing apoptotic death of these 
cells, thus generating opportunities for antigen presentation to stimulate an adaptive immune 
response. Overall, this combination therapy shows promise as a potential adjunct host-directed 
therapy to be tested in in vivo models.  
Limitations 
However, there are some limitations to consider. The first limitation is related to the 
treatment. While the biologically relevant metformin dose is 12uM, our data revealed the optimal 
in vitro dose in combination with 2DG to be 600uM after 24 hours. This dose is 50 times higher 
than what is achievable in vivo, but is still less than concentrations used by other published 
studies (1 or 2mM). Another consideration is that the treatment was added 4 hours post-
infection, thus the observed treatment outcomes may be different if added after longer periods 
of infection. A final consideration related to treatment is the addition of the compounds. In this 
study, they were simultaneously added to cell culture, but treatment outcomes may be 
enhanced or minimized according to how and when each compound is added. 
The second set of limitations is associated with the use of an in vitro versus in vivo 
model. Under an in vitro system, there is not a continuous influx and efflux of nutrients, 
byproducts, and compounds as there would be in vivo. Therefore, we do not know how 
metformin and 2DG function under dynamic conditions such as contact time and accumulation 
among infected cells. We also do not know if the cell death trends noted in vitro will be reflected 
in vivo. A final and important consideration is the absence of a complete immune response 
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within an in vitro model. If the combination of metformin and 2DG potentiates antigen 
presentation via apoptosis, we do not know if bacterial clearance will be augmented via the 
initiation of adaptive immune responses. Despite these limitations, this study provides sufficient 




























The purpose of this project was to determine if a combination treatment of metformin 
and 2-deoxyglucose (2DG) would aid in bacterial clearance through host-directed apoptotic cell 
death. To test this hypothesis, we determined the metabolic status of uninfected compared to 
Mycobacterium tuberculosis (Mtb) infected macrophages under physiologic normal (100mg/dL) 
and high glucose (200mg/dL) conditions as are present under acute and chronic TB infection, 
respectively. We measured the basal respiration and glycolytic activity of these macrophages 
under these various conditions over 72 hours. It was observed that infected macrophages have 
a sustained increase in both basal respiration and glycolytic rates over 72 hours, but that high 
glucose conditions impaired early glycolytic and respiratory responses to infection.  
Next we determined the impact metformin, 2DG, and metformin-2DG combined 
treatments had on Mtb and macrophage metabolism. The three treatments had no effect on Mtb 
growth or metabolism, but had notable effects on macrophage metabolism. In Mtb-infected 
macrophages, metformin treatment alone decreased basal respiration, but increased glycolysis 
in a dose-dependent manner at both 4 and 24 hours post treatment. 2DG showed little effect on 
basal respiration, but effectively inhibited glycolytic activity after just 4 hours of treatment. Both 
treatment outcomes are consistent with each compound’s mechanism of action. Combined, 
metformin-2DG treatment significantly inhibited basal respiration after 4 and 24 hours post-
treatment, and inhibited glycolytic activity as efficiently as 2DG treatment alone. This suggests 
that both compounds work with equal or greater efficacy in combination. Metformin-2DG 
treatment in Mtb-infected macrophages sustained basal respiration and glycolytic inhibition over 
72 hours, but became ineffective in uninfected macrophages after 24 hours, suggesting a 
targeted treatment for pro-inflammatory cells with increased glycolytic metabolism.  The 
combined treatment worked best under a normal glucose condition, demonstrating that the 
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blood glucose lowering impact of metformin would potentiate its cellular effects in conjunction 
with 2DG. 
A final assessment was performed on macrophage and Mtb viability after treatment with 
metformin, 2DG, or metformin-2DG under both glucose conditions. Metformin did not 
significantly impact cell viability, while 2DG and metformin-2DG treatments caused 90% and 30-
35% losses in cell viability, respectively. Discriminating between methods of cell death, 2DG 
metformin-2DG treatment revealed similar levels of apoptosis and inhibition of autophagy. This 
suggests that decreased Mtb viability in metformin-2DG treated cells is not associated with 
apoptosis or autophagy. However, these results also suggest that the combined metformin-2DG 
treatment may be effective at increasing antigen presentation if presented with adaptive immune 
cells.   
Future investigation on this topic should include varying the administration of metformin-
2DG combination treatment in vitro and attempting this treatment in vivo. An additional in vitro 
study should be performed to determine how the order and timing of treatment affects treatment 
outcomes. The addition of either metformin and/or 2DG first may either enhance or decrease 
treatment efficacy. Also, the addition of these compounds after 24, 48, or 72 hours of infection 
may also affect macrophage bacterial clearance. Another in vitro study should determine if cell-
mediated immunity is increased by metformin-2DG treatment. To test this hypothesis, 
lymphocytes would be added to Mtb-infected macrophages and treated with metformin-2DG to 
assess lymphocyte activation, proliferation and metabolic responses. 
In vivo, metformin-2DG treatment should be assessed under both acute and chronic 
infection as well as in combination with first-line TB antimicrobial drugs, including rifampicin, 
pyrazinamide, and isoniazid. First, the effects of order, timing, and duration of treatment would 
need to be determined in terms of Mtb clearance and animal health status. Once a treatment 
regimen is generated, assessment of metformin-2DG treatment on antimicrobial drug efficacy, 
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Mtb clearance, and cell-mediated immune responses would determine the viability of these 
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